The gene editing space is full of exciting investment opportunities, but it isn't exactly a low-risk industry. In this Fool Live video clip, recorded on May 24, Fool.com contributor Brian Orelli, PhD, along with Healthcare Bureau Chief Corinne Cardina and Chief Growth Officer Anand Chokkavelu discuss how investors should best approach it. Anand Chokkavelu: Then as we look to fit this in part of a larger portfolio, assuming the folks are more like me where it's not your focus but you want to have but you've liked the idea of the technology.
There are some big opportunities in the gene editing space over the coming decades. In this Fool Live video clip, recorded on May 24, Fool.com Healthcare Bureau Chief Corrine Cardina, contributor Brian Orelli, PhD, and Chief Growth Officer Anand Chokkavelu discuss Editas Medicine (NASDAQ: EDIT) and why it could be a good stock to put on your radar. Editas has a strong pipeline further out.
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.